Madrigal Pharmaceuticals (MDGL) Return on Capital Employed (2011 - 2026)
Madrigal Pharmaceuticals' (MDGL) quarterly Return on Capital Employed came in at 34.63% in Q1 2026, up 1525.0% year-on-year from 2.13% in Q1 2025, and down 15.5% on a QoQ basis from 29.99% in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Return on Capital Employed (2011 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 16 years of Return on Capital Employed data on file, last reported at 34.63% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 1525.0% year-over-year to 34.63% in Q1 2026; TTM through Mar 2026 was 34.63%, a 1525.0% increase from a year earlier, with the FY2025 full-year figure at 35.7%, up 3838.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 34.63%, down from 29.99% in the prior quarter.
- Over the last five years, Return on Capital Employed for MDGL reached as high as 29.99% in Q4 2025 and fell as low as 307.99% in Q3 2022.
- Historically, Return on Capital Employed has averaged 109.88% across 5 years, with a median of 60.8% in 2024.
- Across the five-year window, Return on Capital Employed slumped 21186 bps in 2022 and surged 14410 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 202.86% in 2022, then soared by 42 bps to 118.64% in 2023, then jumped by 53 bps to 56.04% in 2024, then soared by 46 bps to 29.99% in 2025, then fell by 15 bps to 34.63% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 34.63% in Q1 2026, 29.99% in Q4 2025, and 38.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 15.54 Bn | - | -34.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.63% |
| Dec 31, 2025 | -29.99% |
| Sep 30, 2025 | -38.56% |
| Jun 30, 2025 | -38.27% |
| Mar 31, 2025 | -49.89% |
| Dec 31, 2024 | -56.04% |
| Sep 30, 2024 | -60.31% |
| Jun 30, 2024 | -54.90% |
| Mar 31, 2024 | -60.80% |
| Dec 31, 2023 | -118.64% |
| Sep 30, 2023 | -204.41% |
| Jun 30, 2023 | -151.78% |
| Mar 31, 2023 | -126.15% |
| Dec 31, 2022 | -202.86% |
| Sep 30, 2022 | -307.99% |
| Jun 30, 2022 | -188.63% |
| Mar 31, 2022 | -144.19% |
| Dec 31, 2021 | -114.28% |
| Sep 30, 2021 | -96.13% |
| Jun 30, 2021 | -88.91% |